

RESEARCH

Open Access



METTL3 promotes non-small cell lung cancer (NSCLC) cell proliferation and colony formation in a m6A-YTHDF1 dependent way

Xuejun Dou[†], Zhiyuan Wang[†], Weiqiang Lu, Libin Miao and Yuefeng Zhao

Abstract

Background: N6-methyladenosine (m6A) is the most common RNA modification, which plays a pivotal role in tumor development and progression. In this study, we assessed the role of m6A methyltransferase METTL3 in FRAS1-involved cell proliferation and colony formation of non-small cell lung cancer (NSCLC) cell lines.

Methods: Cell viability was analyzed by Cell Counting Kit (CCK-8) and colony formation. M6A RNA immunoprecipitation (IP), Ribosomal immunoprecipitation, RNA immunoprecipitation (RIP) were performed to verify the relationship between METTL3, FRAS1 and YTHDF1. Rescue experiments to confirm the regulatory mechanism of METTL3-FRAS1 promoted NSCLC cell proliferation through CDON by cooperating YTHDF1.

Results: We found that FRAS1 was correlated with poor prognosis in NSCLC patients, of which the transcript undergoes m6A modification regulated by METTL3. METTL3 silence reduced cell viability of NSCLC cells HCC827 and NCI-H1975, which could be restored by FRAS1 overexpression. The m6A modification of FRAS1 could be recognized by YTHDF1. FRAS1 silence or YTHDF1 silence could rescue the elevated NSCLC cell proliferation, colony formation, and tumor growth induced by METTL3 overexpression in vitro and in vivo.

Conclusions: Our study reveals that METTL3-FRAS1 plays a crucial role in NSCLC cell proliferation, colony formation, and tumor growth through the regulation of CDON by cooperating YTHDF1.

Keywords: METTL3, Non-small cell lung cancer (NSCLC), Cell proliferation, Colony formation, YTHDF1, FRAS1, CDON

Introduction

N6-methyladenosine (m6A) modification has been identified to play a vital role in tumorigenesis [1–3]. Abnormal m6A modifications have been reported to be associated with glioblastoma (GBM), ovarian cancer, bladder cancer, gastric cancer, pancreatic cancer and so on [4–6]. Existing studies showed that m6A modification acts the dual roles in cancers. Nonetheless, there are still

largely unknown about the role, the mechanism and the clinical value of m6A in lung cancer.

M6A modification is regulated by specific methyltransferases (referred to as “writers”), m6A recognition proteins (referred to as “readers”) and demethylases (referred to as “erasers”). METTL3 is the first identified methyltransferase which is responsible for m6A modification. Emerging evidence have shown that METTL3 plays multiple functions in tumorigenesis [7, 8]. For instance, METTL3 promotes liver cancer progression via regulating SOCS2 expression in an m6A-dependent manner [9]. In gastric cancer (GC), METTL3 promotes cell proliferation and liver metastasis in GC by enhancing m6A modification and stability of *HDGF* [10]. It is reported

[†]Xuejun Dou and Zhiyuan Wang these authors have contributed equally to this work.

*Correspondence: douxj08@163.com

Department of Thoracic Surgery, Aerospace Center Hospital, Beijing, China



that METTL3 accelerates colorectal cancer progression by inducing m6A modification of *GLUT1* and activating mTORC1 signaling [11]. METTL3 is also found to facilitate breast cancer tumorigenesis by regulating Bcl-2 [12]. Recent research reveals that METTL3 is upregulated in lung cancer [13]. METTL3-induced m6A methylation of lncRNA ABHD11-AS1 could promote cell proliferation and Warburg effect of NSCLC [14]. These studies indicate that METTL3-modulated m6A mRNA methylation plays vital roles in human tumors including lung cancer.

YT521-B homology (YTH) domain-containing proteins (YTHDFs) YTH could recognize and regulate the effects of RNA m6A modification. YTHDF2 is the first reported m6A reader and studies have shown that YTHDF2 promotes tumorigenesis in multiple cancers [2]. For example, YTHDF2 could promote glioblastoma growth by remaining the stability of *MYC* and *VEGFA* transcripts in an m6A-dependent way [15]. In hepatocellular carcinoma (HCC), one research shows that YTHDF2 expression has a positive correlation with HCC progression [16] whereas another research reports that YTHDF2 suppressed HCC tumor growth through accelerating *EGFR* mRNA degradation [17]. Except for YTHDF2, the YTHDFs family contains YTHDF1, YTHDF3, YTHDC1. It is reported that YTHDF1 functions as a tumor promoter in various cancers such as gastric cancer [18], HCC [19, 20], NSCLC [21]. Up to now, little is known about the role of YTHDF1 in NSCLC.

Fraser extracellular matrix complex subunit 1 (FRAS1) has been reported to be essential for embryonic epithelial-mesenchymal integrity [22]. Recent studies show that FRAS1 contributes to the malignant phenotype of NSCLC [23], gastric cancer [24], colorectal cancer [25].

In this study, we explored the role and the potential molecular mechanism of FRAS1 in NSCLC. Our data demonstrates that m6A methyltransferase METTL3 induced *FRAS1* m6A modification and protein stability, thus accelerating NSCLC cell proliferation.

Methods

Data analysis

The overall survival analysis of FRAS1 in non-small-cell lung cancer (NSCLC) was assessed by using the online survival analysis tool Kaplan–Meier plotter (<https://kmplot.com/analysis/index.php?p=background>) [26], containing the clinical information of NSCLC patients (<https://kmplot.com/analysis/index.php?p=service&caner=lung>) [27]. The NSCLC patients were divided into two groups by the medium expression of FRAS1. The hazard ratio (HR) with 95% confidence intervals (CIs) and log rank p value were labeled in the curve. The JetSet probe set for FRAS1 (220910_at) was used for analysis. Pearson correlation analysis was performed to identify

co-expressed genes related to METTL3 and YTHDF1 with a cut-off of the $|\text{Pearson } R| > 0.3$ and $P < 0.05$ in TCGA-LUAD&LUSC dataset. According to the correlation coefficient for METTL3 greater than 0.6, correlation coefficient for YTHDF1 greater than 0.45, and P value less than 0.001, the intersection genes were screened out and listed in the Additional file 1: Table S1.

Human tissues and cell lines

This study includes five pairs of lung adenocarcinoma (LUAD) tissues from Space Central Hospital. The ethical approval for this study was from Space Central Hospital (20,200,511-JJHZ-01). Written informed consents were obtained from each patient. Four NSCLC cell lines (A549, NCI-H1299, HCC827, and NCI-H1975) and human bronchial epithelial cell line HBEC were obtained from Procell Life Science&Technology Co.,Ltd (Wuhan, China). A549 cells were cultured in DMEM (High glucose, Gibco, Grand Island, NY, USA, 11,965–092) with 10% FBS (Gibco) and 1% penicillin/streptomycin (P/S, Procell). NCI-H1299, HCC827, and NCI-H1975 cells were cultured in RPMI-1640 medium (Gibco) with 10% FBS (Gibco) and 1% penicillin/streptomycin (P/S, Procell). HBEC cells were cultured in the bronchial epithelial growth medium (BEGM, Lonza, CC-3170). All the cells were cultured at 37 °C in a 5% CO₂ incubator.

Stable cell lines

shMETTL3, shYTHDF1, shFRAS1 and shScramble were synthesized from RiboBio (Guangzhou, China), which were cloned into the vector pLKO.1 puro. The stable cell lines such as shMETTL3, shYTHDF1, shFRAS1 and shscramble were generated by infecting these corresponding lentivirus. Two days after infection, the puromycin (1 µg/mL) was added. The shRNA sequences were shown in Table 1.

Quantitative Reverse Transcription-Polymerase chain reaction (qRT-PCR)

Total RNA was isolated using Trizol (Beyotime, Shanghai, China) and reverse transcription was performed with the EasyScript® First-Strand cDNA Synthesis SuperMix (Transgen, Beijing, China). Quantitative real-time PCR analysis was performed with the TransStart® Green qPCR SuperMix (Transgen). The relative expression of each gene was analyzed by the standard $2^{-\Delta\Delta C_t}$ method [28] and normalized to GAPDH. The sequences of qPCR Primers were listed in Table 2.

Western blot

Cells were lysed and proteins were extracted using the ice-cold lysis buffer. The equal amount of proteins were separated by 6% or 10% SDS-PAGE and transferred to

Table 1 Sequences of shRNAs

Target	Oligos
shMETTL3	5'-ACCTCGCTGCAC TTCAGACGAATTATTC AAGAGATAATTCGCTGAAGTGCAGCTT-3' 5'-CAAAAAGCTGCAC TTCAGACGAATTATCTCTTGAATAATTCGCTGAAGTGCAGCG-3'
shYTHDF1	5'-ACCTCGCTGGAGAATAACGACAACAATCAAGAGTTGTTGTCGTTATTCTCCAGCTT-3' 5'-CAAAAAGCTGGAGAATAACGACAACA ACTCTTGATTGTTGTCGTTATTCTCCAGCG-3'
shFRAS1	5'-ACCTCGCTAGTGAAGTTAAACGTATTTC AAGAGAATACGTTTAACTTCACTAGCTT-3' 5'-CAAAAAGCTAGTGAAGTTAAACGTATTCTCTTGAATAACGTTTAACTTCACTAGCG-3'
shscramble	5'-ACCTCGCGCATCGATTGCATAC TATATCAAGAGTATAGTATGCAATCGATGCGCTT-3' 5'-CAAAAAGCGCATCGATTGCATAC TACTCTTGATATAGTATGCAATCGATGCGCG-3'

Table 2 Primers used for quantitative polymerase chain reaction

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
FRAS1	CTAGCGTTGGCGGAATTTGC	GCATTGGTTGGCAGCTATTTGA
METTL3	TTGTCTCCAACCTTCCGTAGT	CCAGATCAGAGAGGTGGTGTAG
YTHDF1	ACCTGTCAGCTATTACCCG	TGGTGAGGTATGGAATCGGAG
CDON	CAGAAACTTGGTGGACCT	GTTATGCAGCCATGAGATACGA GTAG
CCND1	GCTGCGAAGTGGAACCATC	CCTCCTTCTGCACACATTTGAA
GAPDH	ATCATCCCTGCCTCTACTGG	GTCAGGTCCACCACTGACAC

nitrocellulose membrane. After blocked with 5% non-fat milk for 1 h at room temperature, membranes were incubated with corresponding primary antibodies at 4 °C overnight. Then the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies and sensed by the enhanced chemiluminescence (ECL) substrates (Beyotime, Shanghai, China). Primary antibodies were as follows: anti-FRAS1 (#ab240583; Abcam, Cambridge, UK), anti-METTL3 (#ab195352; Abcam), anti-YTHDF1 (#ab252346; Abcam), anti-RPL-22 (#ab77720; Abcam), anti-CDON (#ab227056; Abcam), anti-CCND1 (#ab16663; Abcam), anti-β-actin (#ab8226; Abcam), anti-α-tubulin (#ab7291, Abcam) and anti-GAPDH (#ab8245; Abcam).

CCK-8 and colony formation

Cell viability was analyzed using the cell counting kit-8 (CCK-8, Beyotime). Cells were seeded in the 96-well plate (2 × 10³/well) and cultured for different time (0, 1, 2, 3, 4 or 5 days). Cells were incubated with 10 μL CCK-8 solution for 1 h. The absorbance at 450 nm was detected using a multimode plate reader.

For colony formation assay, cells were plated at a density of 4 × 10³/well in the 6-well plate with complete medium. After 2 weeks, cells were fixed with paraformaldehyde and then stained with 0.1% crystal violet. The colonies images were determined by using a camera.

EDU incorporation

The chamber slides were coated with poly-D-lysine and matrigel. HCC827 and NCI-H1975 cells were seeded on the coated slides. The next day, cells were transfected with si-CDON or si-NC plasmids. After transfection for 48 h, EDU was added for 4 h before fixation. Cells were incubated with fixative solution for 15 min and permeabilized for 20 min. Then the reaction mix was used to fluorescently label EDU for 30 min. Cells were stained for DAPI for 30 min. After that, the EDU positive cells were analyzed using fluorescence microscope, ImageJ software and GraphPad Prism 8.0. The EDU incorporation was performed using Edu staining proliferation kit (Abcam, ab222421).

RNA immunoprecipitation (RIP)

RIP was performed with EZ-Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA). Cells were lysed with specially formulated RIP lysis buffer. Cell lysates were incubated with the indicated antibodies together with the mixed protein A/G-beads at 4 °C overnight. The precipitated RNA was examined by qRT-PCR.

RNA stability assays

HCC827 or NCI-H1975 cells were treated with actinomycin D (5 μg/mL, Sigma) for 0, 2, 4, 6 h. Total RNA was extracted by TRIzol and analyzed by qRT-PCR.

m6A RNA immunoprecipitation assay (MeRIP)

Total RNA was isolated using TRIzol (Beyotime) and then sonicated into RNA fragments. Then, the RNA fragments were incubated with the antibody against m6A (ab208577, Abcam) together with protein A beads at 4 °C for 10 h. The protein-RNA complex was washed

and treated with proteinase K. The immunoprecipitated RNA was detected by qRT-PCR.

Ribosomal immunoprecipitation

HCC827 or NCI-H1975 cells with stable shYTHDF1 or shscr were transfected with RPL22-Myc (Origene, Beijing, China). For 48 h later, cells were lysed using RIPA buffer and then incubated with anti-Myc antibody (Abcam) mixed with protein A beads at 4 °C for 8 h. The normal mouse immunoglobulin G (IgG) was used as control. The protein-RNA complex was washed and treated with proteinase K. The immunoprecipitated RNA was detected by qRT-PCR.

Xenograft tumor models

Twenty BALB/c nude mice (6–8 weeks old) were purchased from Beijing Viewsolid Biotechnology Co. LTD (Beijing, China). Mice were randomly divided into four groups (five mice/group). The stable cells of NCI-H1975/Vector + sh-NC, NCI-H1975/METTL3 + sh-NC, NCI-H1975/METTL3 + sh-YTHDF1, and NCI-H1975/METTL3 + sh-FRAS1 were infected and constructed by using lentivirus (Gene Pharma, Shanghai, China). The xenografts in each group were established by using subcutaneous injection with approximately 1×10^6 cells in each mouse. Tumor volume was measured every 7 days. The tumor volume was calculated as $1/2 \times \text{length} \times \text{width}^2$. The tumor weight was recorded 28 days after inoculation.

Statistical analysis

All experiments were independently repeated at least three times. Data was analyzed using GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA). Group differences were analyzed using Student's t-test. The correlation between FRAS1 and CDON expression was tested via starbase RNA-RNA module (<https://starbase.sysu.edu.cn/index.php>). $P < 0.05$ was considered to be statistical significance.

Results

N6-methyladenosine (m6A) modification and protein level of FRAS1 is upregulated in NSCLC

We used TCGA-LUAD/LUSC database to analyze the correlated genes with METTL3 and YTHDF1, respectively. FRAS1 was identified to be the gene most associated both with METTL3 and YTHDF1 in non-small cell lung cancer (NSCLC) as shown in Fig. 1A ($R_{\text{METTL3}} = 0.730$, $R_{\text{YTHDF1}} = 0.452$, $P < 0.001$, Additional file 1: Table S1). Next, we found an interesting phenotype that the mRNA level of FRAS1 was significantly

lower in 106 paired of NSCLC tumor tissues than that in the corresponding normal tissues (Fig. 1B) whereas the Kaplan–Meier plotter analysis indicated that high FRAS1 expression was associated with shorter overall survival of NSCLC patients (log rank $P = 7e-04$, <https://kmplot.com/analysis/>, Fig. 1C), suggesting that FRAS1 might be a risk prognosis biomarker in NSCLC. We wondered whether there was m6A modification of FRAS1 mRNA in lung cancer. Then, we evaluated the expression of FRAS1 and its m6A level in our collected LUAD samples. Consistent with the public database analysis, FRAS1 mRNA level was decreased in tumor tissues compared to normal tissues (Fig. 1D). However, the m6a level and the protein level of FRAS1 was significantly increased in 3 cases of tumor tissues compared to the paired corresponding normal tissues (Fig. 1E, F). A similar result was also observed in NSCLC cell lines. FRAS1 mRNA level was decreased in NSCLC cell lines A549, HCC827, NCI-H1975 and NCI-H1299 compared to the human bronchial epithelial cells HBEC (Fig. 1G). The m6A level and protein level of FRAS1 in NSCLC cell lines were higher than in HBEC (Fig. 1H, I). These results suggest that m6A modification of FRAS1 mRNA and its protein level was obviously increased in NSCLC tumor tissues.

METTL3 induces FRAS1 mRNA m6A modification

Emerging studies show that m6A plays a critical role in messenger RNA (mRNA) by regulating mRNA process, translation or decay [3]. For example, m6A may accelerate the processing time of mRNA precursors and promote mRNA transport and nucleation speed in cells [29, 30]. To investigate the regulatory mechanism of the m6A modification on FRAS1 mRNA, we focused on the m6A “writer” METTL3. We observed that METTL3 was highly expressed in NSCLC tumor tissues compared to normal tissues (Fig. 2A). The m6A modification sites of FRAS1 mRNA were predicted by SRAMP (<http://www.cuilab.cn/sramp/>) [31], of which the consensus motif were near the terminator (Fig. 2B). To verify the presence of FRAS1 mRNA m6A methylation, we performed the m6A immunoprecipitation using m6A antibody. The immunoprecipitated RNA fragments were detected by qRT-PCR as shown in Fig. 2C and 2D. The m6A modification of FRAS1 mRNA was both detected in HCC827 and NCI-H1975 cells (Fig. 2C). Moreover, the m6A methylation level in shMETTL3 cells (HCC827 and NCI-H1975) was remarkably reduced than the shscr group (Fig. 2D). There was 80% knockdown efficiency of shMETTL3 which was validated by qPCR and western blot (Fig. 2E). Above





Fig. 1 N6-methyladenosine modification and the protein expression of FRAS1 was increased in NSCLC tumor tissues and cell lines. **A** Venn diagram showed the intersection of the co-related genes with METTL3 and the co-related genes with YTHDF1 in lung cancer. There are six genes in the intersection list. FRAS1, PLA2G3, BTNL2, RPAP3, MS4A2, and TAGLN. **B** The mRNA level of FRAS1 was analyzed in paired NSCLC tumor tissues and normal tissues (n = 106) via TCGA. **C** The overall survival of NSCLC patients with FRAS1 expression was analyzed by using Kaplan–Meier plotter. Hazard ratio (HR) = 1.24, 95% Confidence Interval (CI) = 1.1–1.41, log rank P = 7e-04. **D** FRAS1 expression at mRNA level was analyzed by qRT-PCR in five pairs of LUAD samples. N: Normal tissues. T: Tumor tissues. **E** The m6A level of FRAS1 was determined by using MeRIP-qPCR in five pairs of LUAD samples. **F** FRAS1 protein level was detected by western blot in five pairs of LUAD samples. **G** FRAS1 expression at mRNA level was analyzed by qRT-PCR in NSCLC cell lines including A549, HCC827, NCI-H1975, and NCI-H1299, and lung epithelial cell line HBEC. **H** The m6A level of FRAS1 was analyzed in the above five cell lines. **I** FRAS1 expression at protein level was detected by western blot in A549, HCC827, NCI-H1975 and NCI-H1299, and HBEC. **P < 0.01, ***P < 0.001 indicates a significant difference between the indicated groups. NS, not significant

all, these results suggest that METTL3 could promote *FRAS1* transcript m6A modification.

METTL3 silence led to the decreased FRAS1 protein expression and cell proliferation

To explore the biological function of METTL3-regulated *FRAS1* m6A modification, we generated the two stabilized METTL3-silenced cells (HCC827 and NCI-H1975). METTL3 was effectively decreased at protein level in

shMETTL3 cells compared to shscr cells together with the reduced FRAS1 expression at protein level (Fig. 3A). There was no effect on the alteration of *FRAS1* mRNA upon METTL3 knockdown (Fig. 3B). Additionally, the protein level of FRAS1 was no longer reduced with the extension time of actinomycin D (ActD) treatment, suggesting that METTL3 regulated FRAS1 expression dependent on the m6A manner but had no direct effect on FRAS1 protein (Fig. 3C). CCK-8 analysis showed



(See figure on next page.)

Fig. 3 *FRAS1* protein not mRNA level was decreased in *METTL3*-silenced cells. **A** The protein levels of *METTL3* and *FRAS1* were measured in *METTL3*-knockdown HCC827 and NCI-H1975 cells. **B** The mRNA level of *METTL3* was determined in sh*METTL3* HCC827 and NCI-H1975 cells by qPCR. **C** The protein level of *FRAS1* was detected in *METTL3*-knockdown HCC827 and NCI-H1975 cells treated with ActD at 0, 30, 60, 120 min. **D** CCK-8 assay was performed in sh*METTL3* HCC827 and NCI-H1975 cells. **E** Colony formation was performed in sh*METTL3* HCC827 and NCI-H1975 cells for 4 days culture. * $P < 0.05$ or ** $P < 0.01$ or *** $P < 0.001$ indicates a significant difference between the indicated groups. ns, not significant

that cell proliferation was decreased in stable *METTL3*-silenced HCC827 and NCI-H1975 cells (Fig. 3D), which was consistent with the colony formation results (Fig. 3E). These results suggest that *METTL3* alters *FRAS1* protein level but not mRNA level and has an inhibiting action on cell proliferation.

YTHDF1 plays a role in m6A-modified *FRAS1* expression

M6A modified RNAs could be recognized and transmitted to the downstream pathway by the m6A reader proteins. YTHDF1 has been identified to be critical for NSCLC proliferation [21] In this study, we found that YTHDF1 was highly expressed in NSCLC tumor tissues compared to normal tissues via UALCAN (Fig. 4A), indicating that YTHDF1 may play a critical role in m6A-regulated *FRAS1* expression. The RIP assay validated that YTHDF1 could bind to *FRAS1* mRNA (Fig. 4B). To investigate the role of YTHDF1 in the regulation of m6A-modified *FRAS1*, we constructed stable YTHDF1-silenced HCC827 and NCI-H1975 cells. qRT-PCR analysis

showed that YTHDF1 was significantly knockdown in shYTHDF1 cells, while *FRAS1* mRNA has no obvious change, but a remarkable decrease at protein level (Fig. 4C). Furthermore, we performed ribosome immunoprecipitation to analyze the YTHDF1-silence effects on the ribosome occupancy on m6A modified *FRAS1* mRNAs. Results indicated that the ribosome occupancy on *FRAS1* mRNA was reduced in YTHDF1-silenced cells compared to control cells (Fig. 4D). As expected, *FRAS1* mRNA stability was not changed when treated with ActD upon loss of YTHDF1, suggesting that YTHDF1 was not involved in *FRAS1* RNA synthesis. Next, to investigate whether YTHDF1 was involved in the regulation of *FRAS1* protein stability, we treated cells with the proteasome inhibitor MG132. We observed that *FRAS1* protein was still decreased in YTHDF1-silenced cells even with MG132 treatment (Fig. 4E), indicating that YTHDF1 could modulate *FRAS1* protein stability not dependent on the protein degradation pathway. These results further suggest that m6A reader protein YTHDF1 may recognize




Fig. 3 (See legend on previous page.)

the m6A modification of FRAS1, which was increased by METTL3.

METTL3 induced FRAS1 m6A modification modulates CDON expression

We found that cell adhesion associated, oncogene regulated (CDON) had a strong positive correlation with FRAS1 by the online bioinformatics analysis. The Pearson analysis showed that CDON was the strongest correlated factor with FRAS1 in NSCLC ($R=0.61$, Fig. 5A). Starbase online database revealed that there was a strong association between FRAS1 and CDON in 526 pairs of NSCLC samples ($r=0.505$, $P<0.001$, Fig. 5B). In addition, FRAS1 overexpression could rescue the CDON protein level in shMETTL3 cells (Fig. 5C). CCK-8 analysis and colony formation analysis revealed that the decreased proliferation caused by METTL3 knockdown could be reversed by FRAS1 overexpression (Fig. 5D, E). These data suggest that METTL3 regulates cell proliferation via FRAS1.

In addition, we also preliminarily explored the biological role of CDON in HCC827 and NCI-H1975 cells by performing loss-of function by introducing siRNA targeting CDON. CDON expression at mRNA and protein level was significantly decreased in si-CDON-transfected cells as shown in Additional file 1: Figs. S1A and 1B. CCK-8 assay results showed that CDON downregulation led to reduced cell proliferation (Additional file 1: Fig. S1C). Consistently, we also observed that EDU positive cells were decreased when CDON was knockdown by performing EDU incorporation (Additional file 1: Fig. S1D). These results suggest that CDON may act as an oncogene in HCC827 and NCI-H1975 cells.

FRAS1 is a target of N6-methyladenosine METTL3 in NSCLC

To further explore METTL3-induced FRAS1 m6A modification in NSCLC cell proliferation, rescue experiments were performed in stable YTHDF1-silence, FRAS1-silence cells by overexpressing METTL3. qRT-PCR results showed that there was no obvious alteration on the mRNA level of FRAS1 in METTL3-overexpression group compared to sh-YTHDF1 + METTL3-overexpression group (Fig. 6A). The upregulated FRAS1 and CDON protein levels induced by METTL3-overexpression could be restored

by YTHDF1 silence or FRAS1 silence (Fig. 6B). Moreover, we also found that the elevated expression of cyclin D1 (CCND1) induced by METTL3 overexpression could be reversed by YTHDF1 knockdown or FRAS1 knockdown. CCND1 which belongs to the highly conserved cyclin family, regulates cell cycle G1/S transition and promotes cell proliferation in multiple tumors [32–34]. Consistently, we also detected CDON, METTL3 and YTHDF1 protein expressions in five collected tumor samples as shown in Additional file 1: Fig. S2. The result showed that CDON expression was upregulated in T1, T2, T3 and T5 tumor tissues compared to their corresponding normal tissues but T4 sample. YTHDF1 and METTL3 expression at protein levels were all upregulated in five tumor tissues compared to their paired normal tissues. Functional studies showed that the METTL3-overexpression induced elevated cell proliferation could also be rescued by YTHDF1 silence or FRAS1 silence analyzed by CCK-8 and colony formation assay (Fig. 6C and D). Moreover, we also validated the expression of CDON, YTHDF1, and METTL3 in collected NSCLC tumor samples. It was observed that CDON, YTHDF1 and METTL3 were highly expressed in cancer tissues compared to that of in corresponding normal tissues (Additional file 1: Fig. S2), suggesting that there was a positive relationship between FRAS1, CDON, and METTL3/YTHDF1. Above all, our data indicate that FRAS1 was a major target of METTL3 regulating NSCLC cell proliferation.

METTL3-induced FRAS1 promotes NSCLC tumor growth in vivo

To confirm the role of METTL3/FRAS1 axis in vivo, we verified its effects on tumor growth using xenograft tumor model. As shown in Fig. 7, the excessive tumor growth induced by METTL3 upregulation was blocked by FRAS1 or YTHDF1 knockdown, including tumor volume and tumor weight (Fig. 7A–C). Consistently, the increased expression of FRAS1 caused by METTL3 overexpression was reduced when FRAS1 or YTHDF1 silence (Fig. 7D). Taken together, METTL3-induced FRAS1 promotes NSCLC tumor growth in vivo.

(See figure on next page.)

Fig. 4 YTHDF1 keeps FRAS1 mRNA stability. **A** The mRNA level of YTHDF1 was analyzed in NSCLC via UALCAN. **B** The FRAS1 enrichment in RIP assay was performed using YTHDF1 antibody and quantified by qPCR. The relative FRAS1 enrichment was normalized to input. **C** The relative expression of YTHDF1 and FRAS1 at mRNA level was determined by qRT-PCR in HCC827 and NCI-H1975 cells with YTHDF1 silence ($n=3$, left). $**P<0.01$. The knockdown efficiency of shYTHDF1 was evaluated by western blot (right). **D** shYTHDF1 stable cells were transfected with plasmid Myc-RPL22 for 48 h. Ribosomal immunoprecipitation was performed using antibody Myc. The relative FRAS1 expression was quantified by qPCR. **E** The mRNA level of FRAS1 was analyzed in shYTHDF1 stable cells with treatment of actinomycin D (5 $\mu\text{g}/\text{ml}$, left). The protein level of FRAS1 was detected in shYTHDF1 cells with or without MG132 (1 μM) for 24 h. GAPDH was used as an internal control. Values are represented as means \pm SD. $*P<0.05$ or $**P<0.01$ or $***P<0.001$ indicates a significant difference between the indicated groups. ns, not significant





Fig. 4 (See legend on previous page.)



Discussion

Lung cancer is considered to be the leading cause of cancer-related death in the world. The dysregulation of m6A modification is strongly associated with various tumor progression. The role of m6A regulators has been extensively reported in multiple tumors. However, not enough is known about the impact of m6A modification in lung cancer. This study addresses the role and functions of METTL3/YTHDF1/FRAS1 m6A in NSCLC cell proliferation.

In this study, we found an interesting phenomenon that there was an obvious difference between mRNA and protein level of FRAS1 in collected LUAD tissues, which was consistent in NSCLC cell lines. That is, there was no significant difference at mRNA level of *FRAS1* between NSCLC tumors and normal tissues whereas FRAS1 at protein level was upregulated in LUAD tumors compared to normal tissues. However, our results were not consistent with the TCGA analysis, of which the mRNA is lower in lung cancer tumor tissues than normal tissues. There




Fig. 6 The enhanced FRAS1 m6A modification induced by METTL3 promotes cell proliferation of NSCLC cells. **A** The associated genes FRAS1, YTHDF1, CDON at mRNA level was analyzed in the following groups of HCC827 cells by qPCR. Ctrl, shscr + METTL3, shYTHDF1 + METTL3, shFRAS1 + METTL3. **B** The protein level of the above genes was measured by western blot in the following groups of HCC827 cells. Ctrl, shscr + METTL3, shYTHDF1 + METTL3, shFRAS1 + METTL3. **C** CCK-8 assay was analyzed in the following groups of HCC827 cells. Values are represented as means ± SD. **(D)** Colony formation was analyzed in the following groups of HCC827 cells. Ctrl, shscr + METTL3, shYTHDF1 + METTL3, shFRAS1 + METTL3. * $P < 0.05$ or ** $P < 0.01$ or *** $P < 0.001$ indicates a significant difference between the indicated groups. ns, not significant

were three possible reasons. The first reason is that the size of our collected sample was small, just five pairs of samples. We would collected more samples to identify

the expression of *FRAS1* mRNA level between tumor tissues and normal tissues. Second, the tumor samples and normal samples were not paired in TCGA database. The

difference in expression of *FRAS1* RNA level between tumor and normal tissues was not accurately reflected. Third, the lung cancer TCGA database includes data from small cell lung cancer (SCLC) as well as data from non-small cell lung cancer (NSCLC). Our collected samples were all NSCLC. The type of lung cancer might lead to the inconstant result between our study and the TCGA data analysis. In addition, the increased *FRAS1* expression was related to the shorter overall survival of NSCLC patients. These results indicated that *FRAS1* might be a tumor-promoter and a potential prognostic factor in NSCLC. *FRAS1* was previously reported to be important in the process of epidermal-basement membrane adhesion during development [35]. Recent studies show that *FRAS1* was associated with tumor metastasis [24, 25, 36]. *FRAS1* was reported to facilitate the liver metastasis of gastric cancer through activating the EGFR and PI3K signaling pathways [24]. In NSCLC, it was found that *FRAS1* knockdown could suppress HCC827 cell migration and invasion by inhibiting FAK signaling [23]. Our gain and loss-of functional studies revealed that *FRAS1* overexpression could rescue decreased cell proliferation caused by *METTL3* knockdown in HCC827 and NCI-H1975 cells. In turn, *FRAS1* silence could reverse the elevated cell proliferation caused by *METTL3* overexpression in NSCLC cells. This was the first to identify the role of *FRAS1* on the promotion of cell proliferation in lung cancer.

We found that there were conserved methylation sites near the stop codon of *FRAS1* mRNA. *METTL3*, known as the key component of N6-methyltransferase complex, mediates tumorigenesis via RNA methylation [37]. In this work, we found that *METTL3* was highly expressed in NSCLC tumors. Methylated RNA immunoprecipitation revealed that *FRAS1* mRNA existed m6A modification mediated by *METTL3*. *METTL3* was reported to have oncogenic or tumor-suppressor roles in a series of tumors. Such as, *METTL3* promotes liver cancer progression by regulating *SOCS2* in an *YTHDF2*-dependent manner [9]. *METTL3* promotes gastric cancer progression by regulating *HDGF* expression dependent on m (6) A modification [38]. In papillary thyroid cancer (PTC), *METTL3* restrained PTC progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration [39]. *METTL3* has been identified to be a therapeutic target for lung cancer. *YAP* could promote the generation of lung cancer stem

cells in a *METTL3*-m6A-*YTHDF3*-dependent manner [14], *METTL3* could reverse gefitinib resistance of NSCLC by β -elemene [40]. Because of its importance in lung cancer, it is essential to investigate its detailed mechanisms. In this study, we observed that *METTL3* knockdown inhibited NSCLC cell lines HCC827 and NCI-H1975 cell proliferation and colony formation. It is the first study about the correlation between m6A modification of *FRAS1* and lung cancer cell proliferation.

It is known that m6A modifiers could influence tumorigenesis in an m6A manner. For example, *METTL3* could promote lung cancer tumor growth and invasion by boosting the translation of EGFR or TAZ transcripts independent of its catalytic activity [13]. In this study, we found that the elevated cell proliferation caused by *METTL3* up-regulation could be restored by *FRAS1* silence or *YTHDF1* silence, indicating that *METTL3* affected NSCLC cell proliferation in a m6A-dependent manner. However, it would be more complete to perform additional studies to identify whether a possible mutual effect of other writers such as *METTL4* over *FRAS1* mRNA is possible or if other readers such as *YTHDF2* are involved.

m6A readers were reported to be responsible for the methylated mRNA fate. Our data first verified that *YTHDF1* could promote the translation of m6A-modified *FRAS1* mRNA. These data were consistent with the previous research [41]. However, the consistency between cellular and tissue level expression of *METTL3*, *YTHDF1* and *CDON* was not verified. Moreover, further biological function controlled by *YTHDF1*-promoted *FRAS1* protein stability deserves detailed study.

The m6A modification is dynamic and reversible, which could be removed by “eraser” m6A demethylase enzymes, such as FTO, ALKBH5 and demethylases et al. It is reported that FTO could promote hepatocellular carcinoma tumorigenesis via triggering PKM2 demethylation [42]. A study reported that ALKBH5 could maintain tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression [43]. In this study, we mainly focused on *FRAS1* m6A modification by “Writers” and “Readers”. It would be interesting to investigate the possible regulatory mechanisms of *FRAS1* modification by eraser enzymes such as FTO, which will be performed in our further project and enrich the regulatory mechanism mediated by *FRAS1* in NSCLC.

(See figure on next page.)

Fig. 7 *METTL3* induced *FRAS1* promotes tumor growth in vivo. **A** Representative images of tumors originated from xenografted NCI-H1975 cells stably expressing Vector + sh-NC, *METTL3* + sh-NC, *METTL3* + sh *YTHDF1*, and *METTL3* + sh-*FRAS1* by subcutaneous injection. **B** The xenograft tumor model was constructed by using H1975 cells stably expressing Vector + sh-NC, *METTL3* + sh-NC, *METTL3* + sh *YTHDF1*, and *METTL3* + sh-*FRAS1* and the tumor volume was measured at the indicated time points 7, 14, 21, 28 days after subcutaneous injection. **C** The tumor tissues were weighed after mice were sacrificed after 28 days. **D** The protein expression of *METTL3*, *YTHDF1*, and *FRAS1* was detected by western blot. * $P < 0.05$ or ** $P < 0.01$ indicates a significant difference between the indicated groups




Fig. 7 (See legend on previous page.)

CDON (cell adhesion associated, oncogene regulated) is a cell surface protein that activates SHH signaling, which plays an important role in endothelium integrity [44, 45]. Nowadays, CDON was identified to participate in tumor progression. It was reported that CDON was involved in tumor cell growth and invasion in prostate cancer [41]. In this study, METTL3/YTHDF1 elevated FRAS1 protein expression, thus accelerating cell proliferation and tumor growth (colony formation). Meanwhile, we observed that FRAS1 modulated CDON expression. The increased expression of CDON in METTL3-overexpression cells was reversed by FRAS1 silence or YTHDF1 silence. These findings were consistent with the previous reports, that is, CDON was crucial for NSCLC cancer cell proliferation and tumorigenesis [41].

To sum up, our study first demonstrates the tumor-promoter role of FRAS1 in NSCLC and provides an m6A-dependent regulatory mechanism by METTL3. The m6A methyltransferase METTL3 promotes FRAS1 protein levels by enhancing FRAS1 mRNA m6A modification and FRAS1 transcript stability. The regulatory network of “writer” METTL3, “reader” YTHDF1, and “target” FRAS1 inspires the understanding of m6A-dependent gene regulatory mechanism in cancer biology, which offers a possibility of m6A regulators as promising biomarkers in NSCLC.

Abbreviations

m6A: N6-methyladenosine; NSCLC: Non-small cell lung cancer; LUAD: Lung adenocarcinoma; FRAS1: Frasier extracellular matrix complex subunit 1; CDON: Cell adhesion associated, oncogene regulated; METTL3: Methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit; YTHDF1: YTH N6-methyladenosine RNA binding protein 1; IP: Immunoprecipitation; RIP: RNA immunoprecipitation; qRT-PCR: Quantitative Reverse Transcription-Polymerase chain reaction; CDS: Coding sequence; HR: Hazard ratio; CI: Confidence Interval; PCR: Polymerase chain reaction; CCK-8: Cell Counting Kit; EDU: 5-Ethynyl-2'-deoxyuridine.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12890-022-02119-3>.

Additional file 1: Supplementary figures and tables.

Acknowledgements

N/A

Author contributions

XD and ZW: project design, literature research, clinical study, data analysis, manuscript writing and revise. WL, LM and YZ: literature research, clinical study, data analysis, and manuscript draft. All authors have read and approved the manuscript.

Funding

N/A.

Availability of data and materials

The datasets generated during the current study are available from the corresponding author on reasonable request.

Declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

The research was carried out in accordance with relevant guidelines and regulations. Ethics approval of the Ethics Committee of Space Central Hospital (20200511-JJHZ-01). Written informed consents were obtained from each patient.

Consent for publication

Not applicable.

Competing interest

The authors declare that they have no competing interests.

Received: 26 October 2021 Accepted: 8 August 2022

Published online: 25 August 2022

References

- Ma Z, Ji J. N6-methyladenosine (m6A) RNA modification in cancer stem cells. *Stem Cells*. 2020;3:4470.
- Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. *Biomed Pharmacother*. 2019;112:108613.
- Gu C, Shi X, Dai C, et al. RNA m(6A) modification in cancers: molecular mechanisms and potential clinical applications. *Innovation (NY)*. 2020;1(3):100066.
- Liu T, Wei Q, Jin J, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. *Nucleic Acids Res*. 2020;48(7):3816–31.
- Han J, Wang JZ, Yang X, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. *Mol Cancer*. 2019;18(1):110.
- Zhang C, Zhang M, Ge S, et al. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer. *Cancer Med*. 2019;8(10):4766–81.
- Chen H, Gao S, Liu W, et al. RNA N6-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the m6A-GLUT1-mTORC1 axis and is a therapeutic target. *Gastroenterology*. 2021;160(4):1284–300.e16.
- Liu S, Zhuo L, Wang J, et al. METTL3 plays multiple functions in biological processes. *Am J Cancer Res*. 2020;10(6):1631–46.
- Chen M, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. *Hepatology*. 2018;67(6):2254–70.
- Vu LP, Pickering BF, Cheng Y, et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. *Nat Med*. 2017;23(11):1369–76.
- Cui Q, Shi H, Ye P, et al. m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. *Cell Rep*. 2017;18(11):2622–34.
- Dong Z, Cui H. The emerging roles of RNA modifications in glioblastoma. *Cancers (Basel)*. 2020;12(3):2205.
- Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m(6A) methyltransferase METTL3 promotes translation in human cancer cells. *Mol Cell*. 2016;62(3):335–45.
- Jin D, Guo J, Wu Y, et al. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. *J Hematol Oncol*. 2019;12(1):135.

15. Li J, Meng S, Xu M, et al. Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels. *Oncotarget*. 2018;9(3):3752–64.
16. Yang Y, Fan X, Mao M, et al. Extensive translation of circular RNAs driven by N6-methyladenosine. *Cell Res*. 2017;27(5):626–41.
17. Zhong L, Liao D, Zhang M, et al. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. *Cancer Lett*. 2019;442:252–61.
18. Bai Y, Yang C, Wu R, et al. YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma. *Front Oncol*. 2019;9:332.
19. Lin X, Chai G, Wu Y, et al. RNA m6A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. *Nat Commun*. 2019;10(1):2065.
20. Zhao X, Chen Y, Mao Q, et al. Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. *Cancer Biomark*. 2018;21(4):859–68.
21. Shi Y, Fan S, Wu M, et al. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. *Nat Commun*. 2019;10(1):4892.
22. Short K, Wiradjaja F, Smyth I. Let's stick together: the role of the Fras1 and Frem proteins in epidermal adhesion. *IUBMB Life*. 2007;59(7):427–35.
23. Zhan Q, Huang RF, Liang XH, et al. FRAS1 knockdown reduces A549 cells migration and invasion through downregulation of FAK signaling. *Int J Clin Exp Med*. 2014;7(7):1692–7.
24. Umeda S, Kanda M, Miwa T, et al. Fraser extracellular matrix complex subunit 1 promotes liver metastasis of gastric cancer. *Int J Cancer*. 2020;146(10):2865–76.
25. Zhi Q, Wan D, Ren R, et al. Circular RNA profiling identifies circ102049 as a key regulator of colorectal liver metastasis. *Mol Oncol*. 2021;15(2):623–41.
26. Lánčzky A, Györfy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. *J Med Internet Res*. 2021;23(7):e27633.
27. Györfy B, Surowiak P, Budczies J, Lánčzky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. *PLoS ONE*. 2013;8(12):e82241.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta Delta C(T)) method. *Methods*. 2001;25(4):402–8.
29. Zhang Y, Geng X, Li Q, et al. m6A modification in RNA: biogenesis, functions and roles in gliomas. *J Exp Clin Cancer Res*. 2020;39(1):192.
30. Zhang H, Shi X, Huang T, et al. Dynamic landscape and evolution of m6A methylation in human. *Nucleic Acids Res*. 2020;48(11):6251–64.
31. Zhou Y, Zeng P, Li YH, Zhang Z, Cui Q. SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. *Nucleic Acids Res*. 2016;44(10): e91.
32. Zhu M, Zhang C, Zhou P, Chen S, Zheng H. LncRNA CASC15 upregulates cyclin D1 by downregulating miR-365 in laryngeal squamous cell carcinoma to promote cell proliferation. *J Otolaryngol Head Neck Surg*. 2022;51(1):8.
33. Quan LL, Liu JY, Qu LX, et al. Expression of Cyclin D1 gene in ovarian cancer and effect of silencing its expression on ovarian cancer cells based on the Oncomine database. *Bioengineered*. 2021;12(2):9290–300.
34. Caudron-Herger M, Diederichs S. Insights from the degradation mechanism of cyclin D into targeted therapy of the cancer cell cycle. *Signal Transduct Target Ther*. 2021;6(1):311.
35. Smyth I, Du X, Taylor MS, Justice MJ, Beutler B, Jackson IJ. The extracellular matrix gene Frem1 is essential for the normal adhesion of the embryonic epidermis. *Proc Natl Acad Sci U S A*. 2004;101(37):13560–5.
36. McGregor L, Makela V, Darling SM, et al. Fraser syndrome and mouse blebbed phenotype caused by mutations in FRAS1/Fras1 encoding a putative extracellular matrix protein. *Nat Genet*. 2003;34(2):203–8.
37. Cai Y, Feng R, Lu T, Chen X, Zhou X, Wang X. Novel insights into the m6A-RNA methyltransferase METTL3 in cancer. *Biomark Res*. 2021;9(1):27.
38. Wang Q, Chen C, Ding Q, et al. METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. *Gut*. 2020;69(7):1193–205.
39. He J, Zhou M, Yin J, et al. METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration. *Mol Ther*. 2021;29(5):1821–37.
40. Liu S, Li Q, Li G, et al. The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β -elemene. *Cell Death Dis*. 2020;11(11):969.
41. Tassinari V, Cesarini V, Tomaselli S, et al. ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. *Genome Biol*. 2021;22(1):51.
42. Li J, Zhu L, Shi Y, Liu J, Lin L, Chen X. m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation. *Am J Transl Res*. 2019;11(9):6084–92.
43. Zhang S, Zhao BS, Zhou A, et al. m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. *Cancer Cell*. 2017;31(4):591–606.e6.
44. Bashamboo A, Bignon-Topalovic J, Rouba H, McElreavey K, Brauner R. A nonsense mutation in the hedgehog receptor CDON associated with pituitary stalk interruption syndrome. *J Clin Endocrinol Metab*. 2016;101(1):12–5.
45. Chapouly C, Hollier PL, Guimbal S, Cornuault L, Gadeau AP, Renault MA. Desert hedgehog-driven endothelium integrity is enhanced by gas1 (growth arrest-specific 1) but negatively regulated by cdon (cell adhesion molecule-related/downregulated by oncogenes). *Arterioscler Thromb Vasc Biol*. 2020;40(12):e336–336e349.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

